Reviva’s Brilaroxazine Continues to Show Promise in Schizophrenia Treatment Study
Reviva Pharmaceuticals, Inc. has recently provided an enrollment update for its open-label extension study evaluating Brilaroxazine in schizophrenia. With 358 patients enrolled and 223 currently receiving treatment across sites in the USA, Europe, and Asia, the study is progressing well.
The company has been diligently working towards advancing the understanding and treatment of schizophrenia. In addition to the enrollment update, Reviva has also announced a virtual Key Opinion Leader (KOL) event to discuss the topline data from the Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia. This event, scheduled for Thursday, February 15, 2024, at 12:00 PM ET, will feature renowned KOLs Larry Ereshefsky, PharmD, BCPP, FCCP, of Follow the Molecule and Mark Opler, PhD, MPH of WCG.
The enrollment progress for the open-label extension study reflects the growing interest and support from patients, healthcare professionals, and researchers worldwide. It demonstrates the potential of Brilaroxazine as a promising therapeutic option for individuals affected by schizophrenia. The study’s multi-national scope also facilitates a comprehensive evaluation of the drug’s efficacy across different geographical regions.
Reviva’s commitment to addressing the unmet medical needs of schizophrenia patients is further highlighted by their decision to host a virtual KOL event. By engaging with top experts in the field, Reviva aims to provide a deeper understanding of the Phase 3 trial results and foster meaningful discussions regarding the potential impact of Brilaroxazine on schizophrenia treatment.
Larry Ereshefsky, PharmD, BCPP, FCCP, known for his expertise in psychopharmacology, and Mark Opler, PhD, MPH, a renowned researcher in mental health, will share their insights on the Phase 3 trial and shed light on the potential implications of Brilaroxazine in the context of current treatment approaches for schizophrenia.
The virtual format of the KOL event ensures accessibility for a global audience, allowing professionals from various regions to learn from the experts’ analysis and perspectives. The collaboration between Reviva Pharmaceuticals, Follow the Molecule, and WCG aims to foster a greater understanding of Brilaroxazine’s potential benefits and contribute to the advancement of schizophrenia treatment.
With the enrollment update and the upcoming KOL event, Reviva Pharmaceuticals continues to make significant progress in their mission to improve the lives of individuals living with schizophrenia. The spotlight on Brilaroxazine’s potential efficacy and the increased awareness resulting from these initiatives provide hope for a future with better treatment options for this complex disorder.
Comments